Shama Khan to Neoplasms
This is a "connection" page, showing publications Shama Khan has written about Neoplasms.
Connection Strength
1,011
-
Exploring therapeutic potential of Rutin by investigating its cyclin-dependent kinase 6 inhibitory activity and binding affinity. Int J Biol Macromol. 2024 Apr; 264(Pt 2):130624.
Score: 0,196
-
Investigating the role of thymol as a promising inhibitor of pyruvate dehydrogenase kinase 3 for targeted cancer therapy. Int J Biol Macromol. 2024 Feb; 259(Pt 2):129314.
Score: 0,194
-
Investigating potential of cholic acid, syringic acid, and mangiferin as cancer therapeutics through sphingosine kinase 1 inhibition. Int J Biol Macromol. 2023 Dec 31; 253(Pt 5):127036.
Score: 0,190
-
Naringenin as a potential inhibitor of human cyclin-dependent kinase 6: Molecular and structural insights into anti-cancer therapeutics. Int J Biol Macromol. 2022 Jul 31; 213:944-954.
Score: 0,173
-
Selective Covalent Inhibition of "Allosteric Cys121" Distort the Binding of PTP1B Enzyme: A Novel Therapeutic Approach for Cancer Treatment. Cell Biochem Biophys. 2019 Sep; 77(3):203-211.
Score: 0,143
-
MAP/Microtubule Affinity Regulating Kinase 4 Inhibitory Potential of Irisin: A New Therapeutic Strategy to Combat Cancer and Alzheimer's Disease. Int J Mol Sci. 2021 Oct 12; 22(20).
Score: 0,041
-
Structure-based investigation of MARK4 inhibitory potential of Naringenin for therapeutic management of cancer and neurodegenerative diseases. J Cell Biochem. 2021 10; 122(10):1445-1459.
Score: 0,041
-
An update on the discovery and development of selective heat shock protein inhibitors as anti-cancer therapy. Expert Opin Drug Discov. 2018 10; 13(10):903-918.
Score: 0,033